Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ingredient: trastuzumab) won a bid from the Brazilian federal government, marking the fifth consecutive year of supply.

As a result, Celltrion's Brazilian subsidiary will exclusively supply 660,000 vials of Herzuma to the federal government until next year.

Celltrion explained that its local network and stable supply chain, established through its Brazilian subsidiary, contributed to securing this contract.

In addition, Celltrion stated that it has agreed to supply an extra 90,000 vials of the autoimmune disease treatment "Remsima" (active ingredient: infliximab) this year, at the request of the Brazilian federal government. 

"We will focus on solidifying the market dominance of existing products like Herzuma, while continuing to achieve results with follow-up products such as Vegzelma, which is scheduled for launch in the second half of this year," said Kang Kyung-Doo, head of Celltrion’s Latin America division.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com